trending Market Intelligence /marketintelligence/en/news-insights/trending/b8j1uWOwARmhAlftZDHVUg2 content esgSubNav
In This List

Former Juniper exec joins 2X Oncology as CEO

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management


Former Juniper exec joins 2X Oncology as CEO

2X Oncology Inc. named George Elston as CEO and a board member.

Elston was previously CFO of Juniper Pharmaceuticals Inc.

2X Oncology is a clinical stage company developing targeted therapeutics that leverage proprietary drug response predictor companion diagnostic technology to address unmet needs in women's cancer.